Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (60022) 60022
Book Review (12171) 12171
Publication (5363) 5363
Newspaper Article (3351) 3351
Newsletter (3318) 3318
Book Chapter (517) 517
Magazine Article (232) 232
Conference Proceeding (215) 215
Trade Publication Article (135) 135
Transcript (131) 131
Book / eBook (106) 106
Dissertation (105) 105
Web Resource (77) 77
Report (56) 56
Government Document (22) 22
Reference (18) 18
Data Set (11) 11
Presentation (2) 2
Streaming Video (2) 2
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (47583) 47583
humans (43069) 43069
male (22073) 22073
hepatitis (21874) 21874
female (21268) 21268
adult (17119) 17119
middle aged (16269) 16269
hepatitis c (13613) 13613
gastroenterology & hepatology (13218) 13218
hepatitis c virus (12211) 12211
health aspects (11314) 11314
hepatitis b (10888) 10888
antiviral agents - therapeutic use (10280) 10280
infection (9068) 9068
interferon (8298) 8298
liver (8213) 8213
animals (7955) 7955
aged (7794) 7794
infections (7722) 7722
infectious diseases (7627) 7627
risk factors (7323) 7323
virology (7045) 7045
hepatitis b virus (7040) 7040
research (6925) 6925
treatment outcome (6706) 6706
analysis (6687) 6687
care and treatment (6311) 6311
viruses (6083) 6083
immunology (5959) 5959
antiviral agents (5890) 5890
hepatitis c, chronic - drug therapy (5810) 5810
therapy (5597) 5597
virus diseases (5371) 5371
liver diseases (5294) 5294
hiv (5131) 5131
drug therapy (5090) 5090
hepacivirus - genetics (4768) 4768
genotype (4756) 4756
virus-infection (4688) 4688
pharmacology & pharmacy (4644) 4644
adolescent (4617) 4617
medical research (4490) 4490
ribavirin (4453) 4453
prevalence (4435) 4435
patients (4378) 4378
drug therapy, combination (4352) 4352
abridged index medicus (4344) 4344
interferon-alpha - therapeutic use (4179) 4179
medicine (4123) 4123
antiviral agents - pharmacology (4083) 4083
cirrhosis (4030) 4030
human immunodeficiency virus--hiv (3962) 3962
hepatocellular-carcinoma (3872) 3872
hepatitis-c virus (3811) 3811
young adult (3792) 3792
hepatitis b, chronic - drug therapy (3777) 3777
proteins (3731) 3731
liver cancer (3723) 3723
liver cirrhosis (3711) 3711
disease (3701) 3701
research article (3627) 3627
hepatitis b virus - genetics (3621) 3621
hepatitis b virus - drug effects (3488) 3488
microbiology (3434) 3434
mice (3430) 3430
hcv (3404) 3404
epidemiology (3364) 3364
studies (3356) 3356
medicine, experimental (3323) 3323
genetic aspects (3322) 3322
biological response modifiers (3304) 3304
retrospective studies (3295) 3295
hepatocellular carcinoma (3292) 3292
hepatitis c - drug therapy (3291) 3291
gastroenterology and hepatology (3269) 3269
hepatology (3234) 3234
lamivudine (3234) 3234
hepacivirus - drug effects (3231) 3231
mortality (3178) 3178
cancer (3170) 3170
viral load (3166) 3166
transplantation (3143) 3143
medicine & public health (3118) 3118
oncology (3111) 3111
ribavirin - therapeutic use (3079) 3079
digestive system diseases (3059) 3059
rna (3002) 3002
replication (2994) 2994
article (2875) 2875
antiviral agents - administration & dosage (2832) 2832
virus (2801) 2801
multidisciplinary sciences (2779) 2779
antigens (2774) 2774
time factors (2762) 2762
medicine, general & internal (2760) 2760
antiviral agents - adverse effects (2694) 2694
prevention (2691) 2691
vaccines (2673) 2673
risk (2670) 2670
human-immunodeficiency-virus (2630) 2630
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (63) 63
Collection Dvlpm't (Acquisitions) - Closed Orders (7) 7
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (66595) 66595
Chinese (461) 461
French (179) 179
German (155) 155
Spanish (147) 147
Japanese (94) 94
Korean (83) 83
Russian (80) 80
Polish (31) 31
Italian (28) 28
Turkish (27) 27
Hungarian (26) 26
Portuguese (15) 15
Dutch (10) 10
Serbian (5) 5
Croatian (4) 4
Persian (3) 3
Czech (2) 2
Danish (2) 2
Hebrew (2) 2
Hindi (2) 2
Norwegian (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Slovak (1) 1
Slovenian (1) 1
Ukrainian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA
by Lucifora, Julie and Xia, Yuchen and Reisinger, Florian and Zhang, Ke and Stadler, Daniela and Cheng, Xiaoming and Sprinzl, Martin F and Koppensteiner, Herwig and Makowska, Zuzanna and Volz, Tassilo and Remouchamps, Caroline and Chou, Wen-Min and Thasler, Wolfgang E and Hus̈er, Norbert and Durantel, David and Liang, T. Jake and Mun̈k, Carsten and Heim, Markus H and Browning, Jeffrey L and Dejardin, Emmanuel and Dandri, Maura and Schindler, Michael and Heikenwalder, Mathias and Protzer, Ulrike
Science, ISSN 0036-8075, 2014, Volume 343, Issue 6176, pp. 1221 - 1228
Current antiviral agents can control but not eliminate hepatitis B virus (HBV), because HBV establishes a stable nuclear covatently closed circular DNA... 
CYTIDINE DEAMINASES | HEPATOCELLULAR-CARCINOMA | FOREIGN DNA | IN-VITRO | REPLICATION | LYMPHOTOXIN-BETA-RECEPTOR | HUMAN HEPATOCYTES | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | HBV INFECTION | TRANSGENIC MICE | Liver - virology | Interferon-alpha - pharmacology | Up-Regulation | Minor Histocompatibility Antigens | Humans | Hepatocytes - metabolism | Proteins | Cytidine Deaminase - biosynthesis | Liver - drug effects | Cell Nucleus - virology | Lymphotoxin beta Receptor - agonists | Hepatocytes - drug effects | Cell Line | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Liver - metabolism | DNA, Viral - metabolism | Interferon-alpha - therapeutic use | Antibodies, Monoclonal | Mice, SCID | DNA, Circular - metabolism | Hepatitis B virus - drug effects | Animals | Hepatitis B - drug therapy | Hepatocytes - virology | Cytidine - metabolism | Lymphotoxin beta Receptor - antagonists & inhibitors | Hepatitis B virus - metabolism | Control | Interferon alpha | Genetic aspects | Circular DNA | Hepatitis B virus | Properties | Liver cells | Hepatitis | Pharmacology | Antiviral drugs | Deoxyribonucleic acid--DNA | Virology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
by Lampertico, Pietro and Agarwal, Kosh and Berg, Thomas and Buti, Maria and Janssen, Harry L.A and Papatheodoridis, George and Zoulim, Fabien and Tacke, Frank and European Assoc Study Liver and European Association for the Study of the Liver and European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 370 - 398
Abstract Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination... 
Gastroenterology and Hepatology | Tenofovir | EASL guidelines | Treatment | HBV reactivation | Entecavir | TAF | HBV DNA | HBsAg | Hepatocellular carcinoma | Interferon | Mother to child transmission | Hepatitis B | CLOSED CIRCULAR DNA | PEGYLATED INTERFERON ALPHA-2A | REDUCES HEPATOCELLULAR-CARCINOMA | ON-TREATMENT PREDICTION | CHRONIC DELTA-HEPATITIS | CORE-RELATED ANTIGEN | RANDOMIZED CONTROLLED-TRIAL | TENOFOVIR DISOPROXIL FUMARATE | NUCLEOS(T)IDE ANALOG THERAPY | PARTIAL VIROLOGICAL RESPONSE | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - therapeutic use | Hepatitis B, Chronic - epidemiology | Europe | Humans | Interferon-alpha - therapeutic use | Male | Hepatitis B, Chronic - virology | Liver Neoplasms - etiology | Pregnancy | Hepatitis B virus - drug effects | Hepatitis B, Chronic - drug therapy | Societies, Medical | Hepatitis B virus - genetics | Female | Carcinoma, Hepatocellular - etiology | Hepatitis B virus - immunology | Infectious Disease Transmission, Vertical - prevention & control | Hepatitis B surface antigen | Viremia | Vaccination | Migration | Chronic infection | Infections | Patients | Epidemiology | Quality of life | Hepatitis B e antigen | Hepatitis | Cirrhosis | Immunosuppression | Chemotherapy | Risk assessment | Clinical medicine | Public health | Deoxyribonucleic acid--DNA | Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
by European Association for the Study of the Liver and European Assoc Study Liver and European Association For The Study Of The Liver and European Association for the Study of the Liver
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 57, Issue 1, pp. 167 - 185
Gastroenterology and Hepatology | EASL guidelines | Nucleoside/nucleotide analogues | Treatment | Hepatitis B virus | Interferon alpha | LIVER-TRANSPLANTATION PATIENTS | CHRONIC DELTA-HEPATITIS | PREVENT PERINATAL TRANSMISSION | HUMAN-IMMUNODEFICIENCY-VIRUS | SUSTAINED VIROLOGICAL RESPONSE | TENOFOVIR DISOPROXIL FUMARATE | E-ANTIGEN SEROCONVERSION | TERM-FOLLOW-UP | HBEAG-NEGATIVE PATIENTS | HBV DNA LEVELS | GASTROENTEROLOGY & HEPATOLOGY | Hepatitis B virus - drug effects | Hepatitis B, Chronic - drug therapy | Antiviral Agents - therapeutic use | Europe | Humans | Hepatitis B, Chronic - physiopathology | Drug Monitoring - methods | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection
by Sulkowski, Mark S and Chuang, Wan-Long and Kao, Jia-Horng and Yang, Jenny C and Gao, Bing and Brainard, Diana M and Han, Kwang-Hyub and Gane, Edward
Clinical Infectious Diseases, ISSN 1058-4838, 11/2016, Volume 63, Issue 9, pp. 1202 - 1204
Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a... 
ALT flare | HBV reactivation | HCV/HBV coinfection | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | Sofosbuvir - therapeutic use | Coinfection | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Middle Aged | Fluorenes - therapeutic use | Hepatitis B - virology | Male | Hepatitis B - complications | Hepatitis B virus - drug effects | Virus Activation - drug effects | Adult | Female | Hepatitis C - complications | Aged | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Complications and side effects | Hepatitis C | Drug therapy | Risk factors | Hepatitis B | Clinical trials | Hepatitis | Prescription drugs | Index Medicus | Brief Reports | HCV | HBV coinfection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based study
by Chang, Fu‐Ming and Wang, Yen‐Po and Lang, Hui‐Chu and Tsai, Chia‐Fen and Hou, Ming‐Chih and Lee, Fa‐Yauh and Lu, Ching‐Liang
Hepatology, ISSN 0270-9139, 09/2017, Volume 66, Issue 3, pp. 896 - 907
Statin use decreases the risk of decompensation and mortality in patients with cirrhosis due to hepatitis C virus (HCV). Whether this beneficial effect can be... 
HEPATOCELLULAR-CARCINOMA | LIVER-TRANSPLANTATION | THERAPY | NITRIC-OXIDE SYNTHASE | INFECTION | COMPENSATED CIRRHOSIS | SIMVASTATIN | GASTROENTEROLOGY & HEPATOLOGY | TRANSCRIPTION FACTOR | KLF2 | REDUCE | Liver Failure - mortality | Follow-Up Studies | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Liver Cirrhosis - mortality | Male | Case-Control Studies | Liver Failure - virology | Hepatitis B, Chronic - physiopathology | Female | Databases, Factual | Hepacivirus - drug effects | Severity of Illness Index | Liver Cirrhosis - drug therapy | Liver Cirrhosis - prevention & control | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Hepatitis B virus - drug effects | Propensity Score | Hepatitis B, Chronic - drug therapy | Liver Cirrhosis - virology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Taiwan | Aged | Liver Failure - prevention & control | Cirrhosis | Hepatitis | Mortality | Chronic infection | Hepatocellular carcinoma | Alcohol | Population studies | Infections | Hepatitis C | Health risk assessment | Statins | Hepatitis B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus
by Volz, Tassilo and Allweiss, Lena and ḾBarek, Mounira Ben and Warlich, Michael and Lohse, Ansgar W and Pollok, Jörg M and Alexandrov, Alexander and Urban, Stephan and Petersen, Jörg and Lütgehetmann, Marc and Dandri, Maura
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 5, pp. 861 - 867
Background & Aims Currently approved antivirals rarely cure hepatitis B virus (HBV) infection. Therefore additional therapeutic strategies interfering with... 
Gastroenterology and Hepatology | Entry inhibitor | cccDNA | Humanized mice | HBV | uPA | CLOSED CIRCULAR DNA | CELLS | PERSISTENCE | DECLINE | LARGE ENVELOPE PROTEIN | REPLICATION | THERAPY | REDUCTION | GASTROENTEROLOGY & HEPATOLOGY | Liver - virology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Liver - pathology | Antiviral Agents - therapeutic use | Lipopeptides - pharmacology | Lipopeptides - therapeutic use | Humans | Hepatocytes - pathology | Treatment Outcome | Mice, SCID | Virus Internalization - drug effects | Hepatitis B virus - physiology | DNA, Viral - blood | Hepatitis B virus - drug effects | Animals | Hepatitis B virus - genetics | Hepatocytes - virology | Mice | Hepatitis B - prevention & control | Virus Replication - physiology | Disease Models, Animal | Antiviral agents | RNA | Circular DNA | Hepatitis B virus | Biological response modifiers | Health aspects | Hepatitis B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
by Liaw, Y.‐F and Jia, J.‐D and Chan, H.L.Y and Han, K.H and Tanwandee, T and Chuang, W.L and Tan, D.M and Chen, X.Y and Gane, E and Piratvisuth, T and Chen, L and Xie, Q and Sung, J.J.Y and Wat, C and Bernaards, C and Cui, Y and Marcellin, P
Hepatology, ISSN 0270-9139, 11/2011, Volume 54, Issue 5, pp. 1591 - 1599
As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa‐2a (PEG‐IFNα‐2a) therapy in hepatitis B e antigen... 
LAMIVUDINE | THERAPY | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | HBV GENOTYPE | Hepatitis B e Antigens - immunology | Drug Administration Schedule | Hepatitis B, Chronic - immunology | Humans | Polyethylene Glycols - adverse effects | Genotype | Male | Drug Monitoring - methods | Recombinant Proteins - adverse effects | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Young Adult | Hepatitis B Antibodies - blood | Hepatitis B virus - drug effects | Hepatitis B, Chronic - drug therapy | Antiviral Agents - adverse effects | Hepatitis B virus - genetics | Adult | Female | Interferon-alpha - adverse effects | Hepatitis B virus - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights